Novo Nordisk A/S (NYSE:NVO)
$ 133.98 1.06 (0.8%) Market Cap: 596.86 Bil Enterprise Value: 594.47 Bil PE Ratio: 46.36 PB Ratio: 41.35 GF Score: 92/100

Q2 2022 Novo Nordisk A/S Earnings Call Transcript

Aug 03, 2022 / 05:30PM GMT
Release Date Price: $49.96 (-12.71%)
Lars Fruergaard Jorgensen;S;President
Novo Nordisk A;CEO & Member of Management Board

/- -

Welcome to this Novo Nordisk's Earnings Call for the first 6 months of 2022 and the outlook for the year. This call follows the early announcement and raised guidance published today. Due to Danish Securities Regulation, we advanced the release that was recently scheduled for tomorrow morning.

My name is Lars Fruergaard Jorgensen, and I'm the CEO of Novo Nordisk. With me today, I have Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla Sylvest; Executive Vice President and Head of North America Operations, Doug Langa; Executive Vice President and Head of Development, Martin Holst Lange; and finally, Chief Financial Officer, Karsten Munk Knudsen. All of us will be available for the Q&A session.

Today's announcement and the slides for this call are available on our website, novonordisk.com. Please note that this call is being webcasted live, and a recording will be made available on our website as well. This call is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot